MPN-RC 118 AVID200 in Myelofibrosis

Sponsor
John Mascarenhas (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03895112
Collaborator
Formation Biologics (Industry), National Cancer Institute (NCI) (NIH), Myeloproliferative Neoplasm Research Consortium (MPN-RC) (Other)
22
Enrollment
1
Location
1
Arm
48.5
Anticipated Duration (Months)
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Increased levels of TGF-β1 were detected in serum, plasma and BM and positively correlated with both grade of BMF and extent of leukemic cell infiltration in the marrow. TGF-β likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. AVID200 is a drug that targets TGF-β1 and TGF-β3. The study team hypothesizes that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation and restore normal hematopoiesis.

This is a first in human, open-label, multicenter, Phase I/Ib trial of AVID200. Patients must have intermediate-2 or higher primary myelofibrosis (PMF), post-essential thrombocythemia or polycythemia-vera related MF (Post ET/PV MF). This study will enroll up to 24 patients. AVID200 is delivered by IV infusion on day 1 of each 3 week cycle.

Detailed Description

This is a first in human, open-label, multicenter, Phase I/Ib trial of AVID200. To date, there is no therapy for MF evaluated in the clinic that clearly demonstrates the ability to target the malignant HSC and result in effective and reproducible bone marrow morphologic, cytogenetic and molecular responses. Medicinal therapies that result in disease course modification are urgently needed in this chronic and progressive myeloid malignancy. TGF-β likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. The study team proposes that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation and restore normal hematopoiesis. AVID200 is a fusion protein containing TGF-β receptor ectodomains fused to a human Fc IgG domain. AVID200 is a potent TGFβ trap with antibody-like properties which has pM potency against two of the three TGFβ ligands, TGFβ1 and β3.

Study Design

Study Type:
Interventional
Actual Enrollment :
22 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase I Study of AVID200 in Patients With Myelofibrosis (Myeloproliferative Neoplasms Research Consortium [MPN-RC] 118)
Actual Study Start Date :
Feb 15, 2019
Anticipated Primary Completion Date :
Aug 1, 2021
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

ArmIntervention/Treatment
Experimental: AVID200

intravenous in dose cohorts of 70mg/m2 or 180 mg/m2

Drug: AVID200
dose cohorts of 21-day cycles

Outcome Measures

Primary Outcome Measures

  1. Maximally tolerated dose (MTD) of AVID200 [After 6 cycles (Each cycle is 21 days)]

    Cohorts of 3 patients with a maximum evaluable sample size of 12 patients and a target toxicity rate of 30% to estimate the MTD. Each cycle is 21 days.

  2. Number of patients with response eligibility for Phase 1b [After 6 cycles]

    Subjects attaining at least a CI (clinical improvement) by IWG/ELN criteria, or a decrease in bone marrow fibrosis by ≥1 grade with otherwise stable disease, will be allowed to continue AVID200 in the extension phase of the trial.

Secondary Outcome Measures

  1. IWG/ELN criteria [After 6 cycles and after 12 cycles (Each cycle is 21 days)]

    response by IWG/ELN criteria at the end of Cycle 6 and Cycle 12. The IWG/ELN criteria: CR (complete remission), PR (partial remission), Clinical improvement, Anemia response, Spleen response, Symptoms response, PD (progressive disease), SD (stable disease), Relapse, Cytogenetic remission, and Molecular remission

  2. Bone marrow fibrosis grade [up to 37 days after 13 cycles (Each cycle is 21 days)]

    bone marrow fibrosis grade at the end of Cycle 6 and 12. Bone marrow fibrosis (MF) is graded as MF-0 to MF-3, with higher number indicating more disease.

  3. Myelofibrosis Symptom Assessment Form (MFSAF) [up to 37 days after 13 cycles (Each cycle is 21 days)]

    MF-SAFv4.0,each of the items are scored 0 to 10, with total summation from 0 to 100, with higher score indicating more symptoms.

  4. EORTC QLQ-C30 [up to 37 days after 13 cycles (Each cycle is 21 days)]

    EORTC QLQ-C30, 28 item scored from 1 (not at all) to 4 (very much), and 2 items scored 1 (very poor) to 7 (excellent). Total score from 28 - 126, with higher score indicating poorer health

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subjects must be ≥18 years of age at the time of signing the Informed Consent Form (ICF)

  • Subjects must voluntarily sign an ICF

  • Subjects must have a pathologically confirmed diagnosis of PMF as per the WHO diagnostic criteria or post ET/PV MF (note that all diagnoses must include the presence of at least Grade 2 marrow fibrosis according to the European Consensus on Grading of Bone Marrow Fibrosis (see Table 6) with intermediate -2 or high risk disease according to the IWG-MRT Dynamic International Prognostic Scoring System (DIPSS) (see Table 7)

  • A bone marrow biopsy must be performed within the 30 day screening period, however, a bone marrow biopsy obtained within 90 days of screening without intervening treatments and approved by the study chair may suffice.

  • Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.

  • Life expectancy of at least six months

  • At least two weeks must have elapsed between the last dose of any MF-directed drug treatments (including investigational therapies and excluding hydroxyurea) and study enrollment

  • Not eligible for ruxolitinib therapy due to a platelet count <50 x 109/L, previously treated and lack/loss of response as defined by at least one of the following:

  1. Treatment for ≥3 months with inadequate efficacy response defined as <10% spleen volume reduction by MRI or <30% decrease from baseline in spleen length by physical examination or regrowth to these parameters following an initial response; and/or

  2. Treatment for ≥28 days complicated by either

  1. Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months) ii. National Cancer Institute (NCI) CTCAE grade ≥ 3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while being treated with a dosage of < 20 mg BID
  • Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia

  • Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if ≤55 years or 12 months if >55 years, must have a negative serum pregnancy test at screening and cycle 1 day 1 and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception include use of oral contraceptives or Depo-Provera, with an additional barrier method (diaphragm with spermicidal gel or condoms with spermicide), double-barrier methods (diaphragm with spermicidal gel and condoms with spermicide), partner vasectomy, and total abstinence.

  • Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.

  • Must have adequate organ function as demonstrated by the following:

  1. ALT (SGPT) and/or AST (SGOT) ≤ 3x upper limit of normal (ULN), or ≤ 4 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis [EMH] related to MF);

  2. Direct bilirubin ≤ 1.5 x ULN; or ≤ 2x ULN (if upon judgment of the treating physician, it is believed to be due to extra-medullary hematopoiesis related to MF or documented Gilbert's syndrome);

  3. Serum creatinine ≤ 2.0 mg/dL;

  4. Platelet count ≥25 x 109/L

  • Ability to adhere to the study visit schedule and all protocol requirements

  • Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:
  • Other invasive malignancies within the last 3 years, except non-melanoma skin cancer and localized cured prostate and cervical cancer.

  • Previous exposure to galunisertib, fresolimumab, sotatercept, or luspatercept.

  • History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months

  • Have moderate or severe cardiovascular disease:

  1. have the presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension

  2. have documented major ECG abnormalities (not responding to medical treatments)

  • Have predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress (for example, family history of aneurysms, Marfan-Syndrome, bicuspid aortic valve, evidence of damage to the large vessels of the heart documented by CT scan/MRI with contrast)

  • Presence of active serious infection;

  • Any serious, unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the subject from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study

  • Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection

  • Organ transplant recipients other than bone marrow transplant

  • Women who are pregnant or lactating

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1Icahn School of Medicine at Mount SinaiNew YorkNew YorkUnited States10029

Sponsors and Collaborators

  • John Mascarenhas
  • Formation Biologics
  • National Cancer Institute (NCI)
  • Myeloproliferative Neoplasm Research Consortium (MPN-RC)

Investigators

  • Study Chair: John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai
  • Study Chair: Ruben Mesa, MD, Mays Cancer Center at UT Health
  • Study Director: Ronald Hoffman, MD, Icahn School of Medicine at Mount Sinai

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
John Mascarenhas, Associate Professor, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:
NCT03895112
Other Study ID Numbers:
  • GCO 07-0548-01401
  • P01CA108671
  • MPN-RC 118
First Posted:
Mar 29, 2019
Last Update Posted:
May 21, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by John Mascarenhas, Associate Professor, Icahn School of Medicine at Mount Sinai
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 21, 2021